

PATENT

Client-Matter No.: 66872-031
(P-AR 5749)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Liang and Woodward)

Serial No.: 10/681,029)

Filed: October 7, 2003)

For: HUMAN PROSTAGLANDIN)
EP₁ RECEPTOR VARIANTS AND)
METHODS OF USING SAME)

Confirmation No.: 8203

Group Art Unit: 1641

Examiner: Unassigned

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 17, 2004.

By: Andrea L. Gashler
Andrea L. Gashler, Reg. No. 41,029

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

February 17, 2004
Date of Signature

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 502624.

Respectfully submitted,

Date: February 17, 2004

Andrea L. Gashler
Andrea L. Gashler
Registration No.: 41,029
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive, Suite 700
San Diego, California 92122

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY CLIENT-MATTER NO: 66872-031 (P-AR 5749)	SERIAL NO. 10/681,029
	APPLICANT: Liang and Woodward	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: October 7, 2003	GROUP: 1641 CONFIRMATION NO.: 8203

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS


EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	Breyer, "Prostaglandin EP ₁ Receptor Subtype Selectivity Takes Shape," <u>Molecular Pharmacology</u> 59:1357-1359 (2001).
	Breyer and Breyer, "G protein-coupled prostanoid receptors and the kidney," <u>Annu. Rev. Physiol.</u> 63:579-605 (2001).
	Coleman et al., "International Union of Pharmacology. Classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes," <u>Pharmacol. Rev.</u> 46:205-229 (1994).
	Fujino et al., "Delayed reversal of shape change in cells expressing FP(B) prostanoid receptors. Possible role of receptor resensitization," <u>J. Biol. Chem.</u> 275:29907-29914 (2000).
	Funk et al., "Cloning and expression of a cDNA for the human prostaglandin E receptor EP ₁ subtype," <u>J. Biol. Chem.</u> 268:26767-26772 (1993).
	Hori et al., "Hypothalamic mechanisms of pain modulatory actions of cytokines and prostaglandin E ₂ ," <u>Ann. NY Acad. Sci.</u> 917:106-120 (2000).
	Lawrence et al., "Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum," <u>Br. J. Pharmacol.</u> 105:271-278 (1992).
	Matsuoka et al., "Impaired adrenocorticotrophic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP ₁ and EP ₃ subtypes," <u>Proc. Natl. Acad. Sci. USA</u> 100:4132-4137 (2003).
	Mutoh et al., "Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis," <u>Cancer Res.</u> 62:28-32 (2002).
	Okuda-Ashitaka et al., "Suppression of prostaglandin E receptor signaling by the variant form of EP ₁ subtype," <u>J. Biol. Chem.</u> 271:31255-31261 (1996).
	Pierce and Regan, "Prostanoid Receptor Heterogeneity Through Alternative mRNA Splicing," <u>Life Sciences</u> 62:1479-1483 (1998).
	Stock et al., "The prostaglandin E ₂ EP ₁ receptor mediates pain perception and regulates blood pressure," <u>J. Clin. Invest.</u> 107:325-331 (2001).

EXAMINER DATE CONSIDERED _____

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]